A major FDA transparency shift is underway for complete response letters (CRLs), with the agency expanding public posting of non-approval letters and improving how sponsors can be held accountable for communicating outcomes. The disclosure initiative began after the FDA posted more than 200 CRLs tied to later-approved applications and then released 89 previously unpublished CRLs for pending or withdrawn reviews. The analysis says the policy is still evolving: openFDA now provides searchable access to CRLs for approved and unapproved applications, while the FDA’s FY 2027 budget request seeks clearer statutory authority for further disclosure. The report also frames the FDA’s approach against the European Medicines Agency’s assessment outputs to argue for standardized decisional summaries, redaction timelines, and better classification. For biotech teams, the update affects how development risk is documented, how investor and scientific communities learn from failed submissions, and how future communication strategies may be constrained as CRL information becomes harder to keep confidential.